公开(公告)号：US20210113585A1

公开(公告)日：2021-04-22

申请号：US17119132

申请日：2020-12-11

申请人： Mirum Pharmaceuticals, Inc.

发明人： Thomas Jaecklin

IPC分类号： A61K31/554 ,  A61K31/4995 ,  A61K31/7042 ,  A61P1/16

摘要： Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg/kg/day.

公开(公告)号：US20200207797A1

公开(公告)日：2020-07-02

申请号：US16696196

申请日：2019-11-26

申请人： Lumena Pharmaceuticals LLC

发明人： Bronislava GEDULIN ,  Michael GREY ,  Niall O'DONNELL

IPC分类号： C07H13/12 ,  C07D295/13 ,  C07D281/10 ,  C07D211/06 ,  C07C279/12 ,  A61K31/7028 ,  C07H15/26 ,  C07D487/08 ,  C07D413/12 ,  C07D401/12 ,  C07D337/08 ,  C07D285/36 ,  C07D211/08 ,  C07D207/04 ,  C07C257/10 ,  A61K45/06 ,  A61K31/7042 ,  A61K31/554 ,  A61K31/5377 ,  A61K31/4995 ,  A61K31/495 ,  A61K31/454 ,  A61K31/4453 ,  A61K31/4436 ,  A61K31/40 ,  A61K31/38 ,  A61K31/155 ,  C07H15/18

摘要： Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20190211045A1

公开(公告)日：2019-07-11

申请号：US16353824

申请日：2019-03-14

申请人： Washington University

发明人： James W. Janetka ,  Zhenfu Han ,  Scott Hultgren ,  Jerome S. Pinkner ,  Corinne Cusumano

IPC分类号： C07H15/20 ,  C07H15/26 ,  A01N43/10 ,  A61K31/706 ,  A61K31/7056 ,  A61K31/7048 ,  A61K31/7042 ,  A61K31/7034 ,  A61K31/505 ,  C07D309/10 ,  C07H15/22 ,  C07H15/207 ,  C07H15/203 ,  A01N55/08 ,  A01N47/36 ,  A01N43/78 ,  A01N43/76 ,  A01N43/54 ,  A01N43/52 ,  A01N43/42 ,  A01N43/38 ,  A01N43/16 ,  C07H19/056

CPC分类号： C07H15/20 ,  A01N43/10 ,  A01N43/16 ,  A01N43/38 ,  A01N43/42 ,  A01N43/52 ,  A01N43/54 ,  A01N43/76 ,  A01N43/78 ,  A01N47/36 ,  A01N55/08 ,  A61K31/505 ,  A61K31/7034 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/7056 ,  A61K31/706 ,  C07D309/10 ,  C07H15/203 ,  C07H15/207 ,  C07H15/22 ,  C07H15/26 ,  C07H19/056

摘要： The present invention encompasses compounds and methods for treating urinary tract infections.

公开(公告)号：US10273260B2

公开(公告)日：2019-04-30

申请号：US15373260

申请日：2016-12-08

申请人： Washington University

发明人： James W. Janetka ,  Zhenfu Han ,  Scott Hultgren ,  Jerome S. Pinkner ,  Corinne Cusumano

IPC分类号： C07H15/20 ,  C07H15/26 ,  A01N43/10 ,  A01N43/16 ,  A01N43/38 ,  A01N43/42 ,  A01N43/52 ,  A01N43/54 ,  A01N43/76 ,  A01N43/78 ,  A01N47/36 ,  A01N55/08 ,  C07H15/203 ,  C07H15/207 ,  C07H15/22 ,  C07D309/10 ,  C07H19/056 ,  A61K31/505 ,  A61K31/7034 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/7056 ,  A61K31/706

摘要： The present invention encompasses compounds and methods for treating urinary tract infections.

公开(公告)号：US20180280421A1

公开(公告)日：2018-10-04

申请号：US15900570

申请日：2018-02-20

申请人： TUFTS UNIVERSITY

发明人： Philip G. Haydon ,  Jinbo Lee

IPC分类号： A61K31/7072 ,  A61K31/7042 ,  C07F9/09 ,  A61K31/7068 ,  A61K31/706 ,  A61K31/7052 ,  C07H19/06 ,  A61K9/00 ,  C07F9/6574 ,  C07F9/6558 ,  C07H19/067 ,  C07D405/04 ,  C07D413/14 ,  C07D405/14 ,  C07F9/22 ,  A61K31/7064

摘要： This disclosure relates to the use of uridine diphosphate (UDP) derivatives, salts and/or prodrugs thereof for the treatment of inflammatory conditions (e.g., psoriasis) and glaucoma, to prodrugs of UDP derivatives, compositions comprising therapeutically effective amounts of those prodrugs of the UDP derivatives and methods of using those prodrugs for treating various disorders including, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma, and inflammatory conditions, e.g., psoriasis and rheumatoid arthritis.

公开(公告)号：US20180169027A1

公开(公告)日：2018-06-21

申请号：US15737594

申请日：2016-06-07

申请人： The Regents of the University of California

发明人： Liangfang Zhang ,  Che-Ming Jack Hu ,  Ronnie H. Fang ,  Brian T. Luk ,  Soracha Kun Thamphiwatana

IPC分类号： A61K9/51 ,  A61K31/337 ,  A61K47/69 ,  A61K31/7042 ,  A61K9/50 ,  A61K45/06 ,  A61P31/04

CPC分类号： A61K9/51 ,  A61K9/5068 ,  A61K9/5084 ,  A61K9/5094 ,  A61K31/337 ,  A61K31/7042 ,  A61K45/06 ,  A61K47/6901 ,  A61K2300/00 ,  A61P31/04 ,  B82Y5/00

摘要： The present invention relates to prevention and/or treatment of infection by a platelet-targeting microbe in a subject. The present invention provides for methods, combinations and pharmaceutical compositions for preventing and/or treating (and/or related uses) infection by a platelet-targeting microbe in a subject, using, inter alia, an effective amount of a nanoparticle comprising a) an inner core comprising a non-cellular material, b) an outer surface comprising a cellular membrane derived from a platelet; and optionally c) an agent for preventing said infection, treating said infection, diagnosing said infection, prognosing said infection and/or monitoring prevention or treatment of said infection. Exemplary platelet-targeting infections include infections by a bacterium, a virus, a fungus and/or a parasite.

公开(公告)号：US09949947B2

公开(公告)日：2018-04-24

申请号：US14651262

申请日：2013-11-28

申请人： Sapiotec GmbH

发明人： Norbert Roewer ,  Jens Broscheit

IPC分类号： A61K31/7048 ,  A61K47/40 ,  A61K31/352 ,  A61K38/19 ,  A61K45/06 ,  A61K38/17 ,  A61K31/7042 ,  A61K47/48 ,  B82Y5/00

CPC分类号： A61K31/352 ,  A61K31/7042 ,  A61K38/1793 ,  A61K38/191 ,  A61K45/06 ,  A61K47/6951 ,  B82Y5/00 ,  A61K2300/00

摘要： The invention relates to a composition comprising a complex of delphinidin and a sulfoalkyl ether-β-cyclodextrin for use in the treatment of malignant melanoma.

公开(公告)号：US09943482B2

公开(公告)日：2018-04-17

申请号：US14770634

申请日：2014-02-26

申请人： UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

发明人： Ramesh C. Gupta ,  Radha Munagala ,  Farrukh Aqil ,  Jeyaprakash Jeyabalan

IPC分类号： C07H21/02 ,  C07H21/04 ,  A61K9/127 ,  A61K31/704 ,  A61K31/7042 ,  A61K9/00 ,  A61K9/51 ,  A61K31/12 ,  A61K31/337 ,  A61K31/343 ,  A61K31/352 ,  A61K31/585 ,  A61K31/7048 ,  A61K31/7105

CPC分类号： A61K9/1276 ,  A61K9/0019 ,  A61K9/0043 ,  A61K9/0053 ,  A61K9/5176 ,  A61K31/12 ,  A61K31/337 ,  A61K31/343 ,  A61K31/352 ,  A61K31/585 ,  A61K31/704 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/7105

摘要： A composition is provided that comprises a therapeutic agent encapsulated by a milk-derived microvesicle. The compositions can include therapeutic agents such as phytochemical agents or chemotherapeutic agents, while the milk-derived microvesicle can be derived from raw milk or colostrum. Further provided are methods for isolating a microvesicle that includes the steps of obtaining an amount of milk, and subjecting the milk to a series of sequential centrifugations configured to yield greater than about 300 mg of microvesicle protein per 100 ml of milk. Methods of modifying an immune response and treating a cancer in which a milk-derived microvesicle composition is administered are also provided.

公开(公告)号：US20170368025A1

公开(公告)日：2017-12-28

申请号：US15698062

申请日：2017-09-07

申请人： Janssen Pharmaceutica NV

发明人： Paul Rothenberg ,  Douglas K. Ways

IPC分类号： A61K31/381 ,  A61K31/19 ,  A61K31/195 ,  A61K31/7042

CPC分类号： A61K31/381 ,  A61K31/19 ,  A61K31/195 ,  A61K31/7042 ,  A61K2300/00

摘要： The present invention is directed to methods for treating hyperuricemia and related disorders, comprising co-therapy with canagliflozin and probenecid.

公开(公告)号：US09770482B2

公开(公告)日：2017-09-26

申请号：US15139066

申请日：2016-04-26

申请人： The University of Houston System

发明人： Zhang Weihua

IPC分类号： A61K38/10 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  C07K7/08 ,  A61K45/06 ,  A61K31/7042 ,  A61K31/70 ,  A61K31/422 ,  A61K31/7034 ,  A61K38/17

CPC分类号： A61K38/10 ,  A61K31/422 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/70 ,  A61K31/7034 ,  A61K31/7042 ,  A61K38/179 ,  A61K45/06 ,  C07K7/08 ,  A61K2300/00

摘要： A compound can destabilize an epidermal growth factor receptor (EGFR) protein and a sodium/glucose co-transporter 1 (SGLT 1) protein. In one embodiment, the compound is a peptide derived from the interacting domain of EGFR. In another embodiment, the peptide is administered to a patient to treat cancer.